• Flanders Investment & Trade
  • Team Vesalius

Prof dr. Luk H. Vandenberghe holds a degree in cellular and genetic engineering from KU Leuven, one of Flanders’ five universities.

Luk Vandenberghe

He is the Grousbeck associate professor in Gene Therapy at Mass Eye and Ear and Harvard Medical School and Director of the Grousbeck Gene Therapy Center there. He is further affiliated as an associate member of the Broad Institute of Harvard and MIT in Boston. For over 20 years, his research has focused on gene therapy. His studies range from the mechanistic to innovative technology discovery and the development of gene therapies to the clinic in several therapeutic areas. 

Dr. Vandenberghe previously co-founded the biotech companies GenSight Biologics, Akouos, Affinia Therapeutics and the non-profit Odylia Therapeutics that seeks to make gene therapy for rare diseases more widely available. Gene therapy technologies from his work are licensed to more than 10 biopharmaceutical companies, is used in over a dozen clinical studies, and is incorporated in one of the first FDA and EMA approved gene therapy drugs. Most recently, his group has led the development of a gene-based vaccine for COVID19.

Team Vesalius visionairies

Flanders’ life sciences industry: the perfect combo of biotech, medtech, pharma and healthcare

Defining Flanders’ life sciences industry as diverse is an understatement. From young start-ups to established local firms and multinationals: the entire value chain – from research and discovery to development and commercialization – is represented in Belgium’s northern region. Thanks to fertile cross-pollination between biotech, medtech, pharmaceuticals and healthcare, Flanders offers a unique life sciences ecosystem that is underpinned by a robust financing landscape and a supportive government. Will your company claim its place in this dynamic hub?